# Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab

> **NCT00891930** · PHASE2 · COMPLETED · sponsor: **NantBioScience, Inc.** · enrollment: 74 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **BIOLOGICAL:** Panitumumab
- **BIOLOGICAL:** Ganitumab
- **DRUG:** Irinotecan

## Key facts

- **NCT ID:** NCT00891930
- **Lead sponsor:** NantBioScience, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05-05
- **Primary completion:** 2013-07-22
- **Final completion:** 2013-07-22
- **Target enrollment:** 74 (ACTUAL)
- **Last updated:** 2024-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00891930

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00891930, "Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00891930. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*